 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Jan 31, 2024
P1, N=50, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2023
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Feb 10, 2023
P1, N=50, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2023 Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Enrollment closed: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Jun 27, 2022
P1, N=43, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Trial completion date: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Jun 3, 2022
P1, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial completion date: Mar 2022 --> Mar 2023
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Journal: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. (Pubmed Central) - Aug 22, 2020
Importantly, we demonstrate that one dose of a commercial rabies vaccine effectively boosts the neutralizing antibody responses induced by ChAd155-RG in vaccinated monkeys, showing the compatibility of the novel vectored vaccine with the current post-exposure prophylaxis in the event of rabies virus exposure. Finally, we demonstrate that antibodies induced by ChAd155-RG can also neutralize European bat lyssaviruses 1 and 2 (EBLV-1 and EBLV-2) found in bat reservoirs.
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
Enrollment open: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Sep 9, 2019
P1, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Finally, we demonstrate that antibodies induced by ChAd155-RG can also neutralize European bat lyssaviruses 1 and 2 (EBLV-1 and EBLV-2) found in bat reservoirs. Not yet recruiting --> Recruiting
- | rabies Vaccine (ChAd155-RG) / National Institute of Allergy and Infectious Diseases
New P1 trial: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - Jul 14, 2019
P1, N=50, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)